MS Drug Tysabri Cuts Hospital Stays
Posted on: Friday, 6 October 2006, 12:00 CDT
U.S. firm Biogen Idec and Irish firm Elan said Friday new data show their multiple-sclerosis drug Tysabri cuts steroid use and hospitalizations.
The companies said data from phase 3 studies of the treatment showed that Tysabri significantly reduced the need for corticosteroids in patients taking the drug and number of hospital stays, and also revealed that a greater percentage of treated patients had no disease activity, meaning no additional relapses or disability progression.
Specifically, data from the phase 3 study showed treated patients saw a 69-percent relative reduction in the annualized rate of relapses requiring steroids, compared to those on placebo, and a 65-percent relative reduction in the annualized rate of MS-related hospitalizations over two years.
The companies said they would present the findings along with data on improved quality of life and cost-effectiveness measures in Tysabri patients at the Academy of Managed Care Pharmacy's 2006 Educational Conference in Chicago.
Source: United Press International
Related Articles
- Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
- GI Dynamics Announces Data Demonstrating Immediate and Sustained Reduction in HbA1c in Patients With Type 2 Diabetes Using EndoBarrier(TM) Gastrointestinal Liner
- MS Drug Tysabri Helps Cognition
- Northwest Biotherapeutics Updates Brain Cancer Clinical Data
- MS Drug is Given Second Chance, but Tysabri Faces FDA Restrictions
- New Data on TYSABRI(R) Demonstrate Significant Effects on Health-Related Quality of Life Measures in Patients With Multiple Sclerosis
- MS drug Tysabri should return to market: panel
- MS drug Tysabri should return to market-US panel
- Elan and Biogen Idec Announce TYSABRI(R) Safety Evaluation Findings in Crohn's Disease and Rheumatoid Arthritis Patients; TYSABRI Safety Evaluation Complete; No New Confirmed Cases of PML
- AVANIR's Pivotal Neurodex Clinical Trial Data Presented at American Academy of Neurology Meeting; Data on the Treatment of PBA in MS Patients Selected As a ``Highlight of the Meeting''
 |
 |
User Comments (0)
RSS Feeds